Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 151

1.

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.

Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N.

Cancers (Basel). 2019 Jul 31;11(8). pii: E1084. doi: 10.3390/cancers11081084.

2.

Radiofrequency ablation for hepatocellular carcinoma: Clinical value of ultrasound-ultrasound overlay fusion for optimal ablation and local controllability.

Minami Y, Minami T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, Kudo M.

Hepatol Res. 2019 Jul 13. doi: 10.1111/hepr.13407. [Epub ahead of print]

PMID:
31301213
3.

Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study.

Ueshima K, Nishida N, Hagiwara S, Aoki T, Minami T, Chishina H, Takita M, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Hiraoka A, Johnson P, Kudo M.

Cancers (Basel). 2019 Jul 7;11(7). pii: E952. doi: 10.3390/cancers11070952.

4.

Switching from entecavir to tenofovir alafenamide versus maintaining entecavir for chronic hepatitis B.

Hagiwara S, Nishida N, Ida H, Ueshima K, Minami Y, Takita M, Komeda Y, Kudo M.

J Med Virol. 2019 Oct;91(10):1804-1810. doi: 10.1002/jmv.25515. Epub 2019 Jul 2.

PMID:
31199513
5.

Contrast-enhanced harmonic endoscopic ultrasonography for evaluating the response to chemotherapy in pancreatic cancer.

Tanaka H, Kamata K, Takenaka M, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Minaga K, Yamao K, Sakurai T, Watanabe T, Nishida N, Chiba Y, Kitano M, Kudo M.

Dig Liver Dis. 2019 Aug;51(8):1130-1134. doi: 10.1016/j.dld.2019.03.015. Epub 2019 Apr 19.

PMID:
31006543
6.

Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease.

Kono M, Sakurai T, Okamoto K, Nagai T, Komeda Y, Kashida H, Minaga K, Kamata K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Enoki E, Inoue H, Matsumura I, Kudo M.

Intern Med. 2019 Jul 15;58(14):2029-2033. doi: 10.2169/internalmedicine.2495-18. Epub 2019 Apr 17.

7.

Clinical Safety and Efficacy of Secondary Prophylactic Pegylated G-CSF in Advanced Pancreatic Cancer Patients Treated with mFOLFIRINOX: A Single-center Retrospective Study.

Yamao K, Takenaka M, Yoshikawa T, Ishikawa R, Okamoto A, Yamazaki T, Nakai A, Omoto S, Kamata K, Minaga K, Hagiwara S, Sakurai T, Nishida N, Chiba Y, Watanabe T, Kudo M.

Intern Med. 2019 Jul 15;58(14):1993-2002. doi: 10.2169/internalmedicine.2234-18. Epub 2019 Apr 17.

8.

Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy.

Minami Y, Nishida N, Kudo M.

Eur Radiol. 2019 Sep;29(9):5045-5051. doi: 10.1007/s00330-019-06189-6. Epub 2019 Apr 8. Review.

PMID:
30963271
9.

Risk factors for local recurrence and appropriate surveillance interval after endoscopic resection.

Komeda Y, Watanabe T, Sakurai T, Kono M, Okamoto K, Nagai T, Takenaka M, Hagiwara S, Matsui S, Nishida N, Tsuji N, Kashida H, Kudo M.

World J Gastroenterol. 2019 Mar 28;25(12):1502-1512. doi: 10.3748/wjg.v25.i12.1502.

10.

Current status and perspectives for computer-aided ultrasonic diagnosis of liver lesions using deep learning technology.

Nishida N, Yamakawa M, Shiina T, Kudo M.

Hepatol Int. 2019 Jul;13(4):416-421. doi: 10.1007/s12072-019-09937-4. Epub 2019 Feb 21.

PMID:
30790230
11.

Efficacy and Safety of Chemotherapy Following Anti-PD-1 Antibody Therapy for Gastric Cancer: A Case of Sclerosing Cholangitis.

Kono M, Sakurai T, Okamoto K, Masaki S, Nagai T, Komeda Y, Kamata K, Minaga K, Yamao K, Takenaka M, Watanabe T, Nishida N, Kudo M.

Intern Med. 2019 May 1;58(9):1263-1266. doi: 10.2169/internalmedicine.1981-18. Epub 2019 Jan 10.

12.

Liver damage related to immune checkpoint inhibitors.

Nishida N, Kudo M.

Hepatol Int. 2019 May;13(3):248-252. doi: 10.1007/s12072-018-9921-7. Epub 2019 Jan 3. Review.

PMID:
30607787
13.

Gankyrin Contributes to Tumorigenesis and Chemoresistance in Sporadic Colorectal Cancer.

Sakurai T, Komeda Y, Nagai T, Kamata K, Minaga K, Yamao K, Takenaka M, Hagiwara S, Watanabe T, Nishida N, Kashida H, Nakagawa K, Kudo M.

Digestion. 2018 Dec 4:1-9. doi: 10.1159/000494969. [Epub ahead of print]

PMID:
30513515
14.

Molecular Scoring of Hepatocellular Carcinoma for Predicting Metastatic Recurrence and Requirements of Systemic Chemotherapy.

Nishida N, Nishimura T, Kaido T, Minaga K, Yamao K, Kamata K, Takenaka M, Ida H, Hagiwara S, Minami Y, Sakurai T, Watanabe T, Kudo M.

Cancers (Basel). 2018 Sep 29;10(10). pii: E367. doi: 10.3390/cancers10100367.

15.

Erythropoietic Protoporphyria-related Hepatopathy Successfully Treated with Phlebotomy.

Yoshida A, Hagiwara S, Watanabe T, Nishida N, Ida H, Sakurai T, Komeda Y, Yamao K, Takenaka M, Enoki E, Kimura M, Miyake M, Kawada A, Kudo M.

Intern Med. 2018;57(17):2505-2509. doi: 10.2169/internalmedicine.0673-17. Epub 2018 Sep 1.

16.

Dysbiosis-Associated Polyposis of the Colon-Cap Polyposis.

Okamoto K, Watanabe T, Komeda Y, Okamoto A, Minaga K, Kamata K, Yamao K, Takenaka M, Hagiwara S, Sakurai T, Tanaka T, Sakamoto H, Fujimoto K, Nishida N, Kudo M.

Front Immunol. 2018 May 7;9:918. doi: 10.3389/fimmu.2018.00918. eCollection 2018.

17.

Cystic duct antegrade stenting for cholangitis after the long-term deployment of lumen-apposing metal stents for calculous cholecystitis.

Kamata K, Takenaka M, Minaga K, Nakai A, Omoto S, Miyata T, Yamao K, Imai H, Sakurai T, Watanabe T, Nishida N, Kudo M.

Endosc Ultrasound. 2018 Sep-Oct;7(5):349-350. doi: 10.4103/eus.eus_91_17. No abstract available.

18.

Immune checkpoint blockade for the treatment of human hepatocellular carcinoma.

Nishida N, Kudo M.

Hepatol Res. 2018 Jul;48(8):622-634. doi: 10.1111/hepr.13191. Epub 2018 Jun 6. Review.

PMID:
29734514
19.

Value of additional endoscopic ultrasonography for surveillance after surgical removal of intraductal papillary mucinous neoplasms.

Kamata K, Takenaka M, Minaga K, Omoto S, Miyata T, Yamao K, Imai H, Nakai A, Tanaka H, Chiba Y, Watanabe T, Sakurai T, Nishida N, Chikugo T, Matsumoto I, Takeyama Y, Kitano M, Kudo M.

Dig Endosc. 2018 Sep;30(5):659-666. doi: 10.1111/den.13176. Epub 2018 May 16.

PMID:
29675938
20.

Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B.

Hagiwara S, Nishida N, Watanabe T, Ida H, Sakurai T, Ueshima K, Takita M, Komeda Y, Nishijima N, Osaki Y, Kudo M.

Antivir Ther. 2018;23(6):513-521. doi: 10.3851/IMP3225.

PMID:
29438098

Supplemental Content

Loading ...
Support Center